Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.

Journal of clinical lipidology - 1 Jan 2000

Orringer Carl E, Jacobson Terry A, Saseen Joseph J, Brown Alan S, Gotto Antonio M, Ross Joyce L, Underberg James A

Abstract excerpt

An Expert Panel convened by the National Lipid Association was charged with updating the recommendations on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy that were provided by the 2015 National Lipid Association Recommendations for the Patient-Centered Management of Dyslipidemia: Part 2. Recent studies have demonstrated the efficacy of these agents in reducing low-density...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atherosclerosis
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Evidence-Based Medicine

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hypercholesterolemia

Share to Protease Inhibitors

Share to Societies, Medical

Source

Identifiers

PMID: 28532784
DOI: 10.1016/j.jacl.2017.05.001

Genes

PCSK9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.PMID 28532784Read ↗

Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).Semantic proximity Read ↗

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.Semantic proximity Read ↗

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.Semantic proximity Read ↗

Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.Semantic proximity Read ↗

The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.Semantic proximity Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.Semantic proximity Read ↗

PCSK9 inhibitors: the next frontier in low-density lipoprotein lowering.Semantic proximity Read ↗

Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Semantic proximity Read ↗

Clinical aspects of PCSK9.Semantic proximity Read ↗

Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.